BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements

Dow Jones

05/21

By Christopher Kuo

BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants.

The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature.

The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span.

The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 20, 2026 16:57 ET (20:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2637136875"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2637136875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2637136875?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 04:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637136875","market":"hk","top_or_hot":-1,"title":"BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants. \n</p>\n<p>\n  The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature. \n</p>\n<p>\n  The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span. \n</p>\n<p>\n  The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2026 16:57 ET (20:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-21 04:57</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants. \n</p>\n<p>\n  The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature. \n</p>\n<p>\n  The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span. \n</p>\n<p>\n  The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2026 16:57 ET (20:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2637136875","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637136875","pubTimestamp":1779310620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants.The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature.The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span.The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BMRN":"拜玛林制药","BK4566":"资本集团","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"BioMarin表示Voxzogo的3期研究显示患者有所改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  BioMarin Pharmaceutical said its phase 3 study of a treatment for a genetic disorder that causes dwarfism showed statistically significant improvements among participants. \n\n\n  The trial evaluated BioMarin's Voxzogo drug among 80 children ages three to 17 with hypochondroplasia, a genetic skeletal disorder that causes short-limbed short stature. \n\n\n  The study met its primary endpoint, demonstrating a statistically significant increase in annualized growth velocity compared with the placebo, BioMarin said. Children who received the drug also showed a statistically significant increase in standing height versus the placebo after a year of treatment as well as improvements in arm span. \n\n\n  The company plans to submit its supplemental new drug application to the Food and Drug Administration in the third quarter, followed by submissions to the European Medicines Agency and other regional health authorities. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 16:57 ET (20:57 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}